Published Papers on Amdoxovir (DAPD)
Amdoxovir (DAPD), RFS Pharma's lead drug candidate, is currently undergoing late Phase II clinical trials.
Please visit www.pubmed.gov for abstracts and/or full text versions of the articles below.
|
Preclinical
Hernandez-Santiago BI, Okikhod A, Fromentin E,
Hurwitz SJ, Schinazi RF. Cellular pharmacology of
9-(b-D-1,3-dioxolan-4-yl)guanine (DXG) and its lack of drug
interactions with zidovudine in primary human lymphocytes. Antivir. Chem. Chemother. 18(6): 343-346, 2007.
Abstract available on PubMed
Menne
S, Asif G, Narayanasamy J, Butler SD, George AL, Hurwitz SJ, Schinazi
RF, Chu CK, Cote PJ, Gerin JL, Tennant BC. Antiviral effect of orally
administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with
chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 51(9): 3177-84, 2007 Sep.
Full Text available in PubMed Central
Hurwitz
SJ, Asif G, Kivel NM, Schinazi RF. Development of an optimized dose for
coformulation of zidovudine with drugs that select for the K65R
mutation using a population pharmacokinetic and enzyme kinetic
simulation model. Antimicrob Agents Chemother. 52(12): 4241-4250, 2008 Dec.
Full Text available in PubMed Central
Fromentin,
E, Asif, G, Obikhod, A, Hurwitz, SJ, and Schinazi, RF.
Simultaneous quantification of 9(-beta-D-1,3-dioxolan-4-yl)guanine,
amdoxovir and zidovudine in human plasma by liquid
chromatography-tandem mass spectrometric assay. J Chromatography B 877(3482-3488), 2009.
Abstract available on PubMed
Fromentin E, et
al. Simultaneous quantification of intracellular natural and
antiretroviral nucleosides and nucleotides by liquid
chromatography-tandem mass spectrometry. Anal Chem. 2010;82(5):1982-9.
PubMed PMID: 20143781.
Abstract available on PubMed
|
ClinicalThompson MA, Kessler HA, Eron JJ Jr, Jacobson JM, Adda N, Shen G,
Zong J, Harris J, Moxham C, Rousseau FS, DAPD-101 Study Group.
Short-term safety and pharmacodynamics of amdoxovir in HIV-infected
patients. AIDS. 19(15): 1607-15, 2005 Oct 14.
Abstract available on PubMed
Gripshover
BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B,
Hammer SM, Kuritzkes DR, A5118 Team. Amdoxovir versus placebo with
enfuvirtide plus optimized background therapy for HIV-1-infected
subjects failing current therapy (AACTG A5118). Antivir Ther. 11(5): 619-23, 2006.
Abstract available on PubMed
Margolis
DM, Mukherjee AL, Fletcher CV, Hogg E, Ogata-Arakaki D, Petersen T,
Rusin D, Martinez A, Mellors JW. The use of beta-D-2,6-diaminopurine
dioxolane with or without mycophenolate mofetil in drug-resistant HIV
infection. AIDS. 21(15): 2025-32, 2007 Oct 1.
Abstract available on PubMed
Murphy,
R.L., Kivel, N.M., Zala, C., Ochoa, C., Tharnish, P., Mathew, J.,
Pascual, M.L., Schinazi, R.F.: Antiviral activity and tolerability of
amdoxovir with zidovudine in a randomized double-blind
placebo-controlled study in HIV-1-infected individuals. Antivir Ther. 15:185-192, 2010.
Abstract available on PubMed
Hurwitz,
S.J., Asif, G., Fromentin, E., Tharnish, P.M. and Schinazi, R.F.: Lack
of pharmacokinetic interaction between amdoxovir and reduced- and
standard-dose zidovudine in HIV-1 infected individuals. Antimicrob. Agents Chemother., 54(1248-1255), 2010.
Abstract avaialble on PubMed Won SY, and
Kessler HA. Amdoxovir. The Use of Antibiotics: A Clinical Review of
Antibacterial, Antifungal and Antiviral Drugs. Sixth edition. Grayson L
et al. October 2010, pages 2627-35. Hodder Arnold publication.
Book chapter available from Hodder education
|
|
